Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Adipotide

Adipotide

Adipotide (FTPP): the 2011 monkey study, the terminated first human trial, kidney toxicity, its unapproved status and sport rules.

Investigational, not approved · Evidence grade D · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes Adipotide only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

Approved and studied uses
  • Not approvedFat lossMonkey data; a small human trial was terminated
Training and drug testingBanned at all times

It is not named on the WADA Prohibited List, but no health authority has approved it for human use, so it falls under class S0 (non-approved substances), banned at all times.

Drug-tested athletes can look up any substance on Global DRO, run by national anti-doping agencies. Supplements can contain banned substances that are not on the label. Drawline does not suggest when to train or inject.

Adipotide (FTPP, prohibitin-targeting peptide 1, Prohibitin-TP01). Experimental fat-targeting peptide.

DInvestigational, not approved. Evidence grade D: animal and lab data only.

What is Adipotide?

Adipotide is an experimental peptide that targets prohibitin, a protein on blood vessels that feed white fat, and makes those vessel cells die. It was developed by Wadih Arap and Renata Pasqualini's group at MD Anderson Cancer Center.

Is Adipotide FDA-approved?

Not approved for any use. A first-in-human phase 1 trial at MD Anderson in men with metastatic prostate cancer and obesity started in 2012 and is listed as terminated, with no published results. No other human trial results have been reported.

What does the evidence show for Adipotide?

In a 2011 study, obese monkeys lost about 11 percent of body weight over four weeks and their insulin resistance improved. Human data are limited to the terminated trial, which reportedly enrolled 4 people and posted no results.

What are the known risks of Adipotide?

In the monkey study, all three species tested showed changes in kidney tubule function at working doses; the changes were predictable and reversible, but kidney harm was the main safety concern. Its safety in people is unknown. Sport: it is not named on the WADA Prohibited List, but no health authority has approved it for human use, so it falls under class S0 (non-approved substances), banned at all times.

How is Adipotide measured?

A powder vial: enter the amount in the vial and the water added, and the calculator shows the syringe units for a prescribed dose. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.

Sources: Barnhart et al., adipotide in obese monkeys, Sci Transl Med (2011); MD Anderson: obese monkeys lose weight on drug that attacks fat blood supply; ClinicalTrials.gov: phase 1 prohibitin-targeting peptide 1 in prostate cancer and obesity (NCT01262664); WADA: 2026 Prohibited List. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.